Table 4.
Patient background factors significantly associated with an Overall Desire and Specific Desire by type of alternative treatment option
| Overall Desire | Specific Desire by type of alternative treatment | |||||||
|---|---|---|---|---|---|---|---|---|
| Change in medication | Hospital transfer | CAM | ||||||
| OR (95% CI) | p-Value | OR (95% CI) | p-Value | OR (95% CI) | p-Value | OR (95% CI) | p-Value | |
| Sex | ||||||||
| Female | Reference | |||||||
| Male | 1.12 (0.73−1.72) | 0.590 | 1.24 (0.92−1.68) | 0.163 | 1.11 (0.86−1.43) | 0.439 | 0.92 (0.73−1.16) | 0.463 |
| Age, years | ||||||||
| < 30 | Reference | |||||||
| 30 −< 40 | 0.79 (0.42−1.50) | 0.386 | 0.98 (0.64−1.50) | 0.652 | 0.75 (0.52−1.09) | 0.016 | 0.85 (0.60−1.18) | 0.015 |
| 40 −< 50 | 0.95 (0.48−1.87) | 1.29 (0.83−2.03) | 0.75 (0.51−1.11) | 0.65 (0.46−0.93) | ||||
| 50 −< 60 | 0.62 (0.29−1.31) | 1.14 (0.67−1.92) | 0.47 (0.30−0.73) | 0.54 (0.36−0.81) | ||||
| ≥ 60 | 0.48 (0.18−1.25) | 1.17 (0.57−2.42) | 0.56 (0.30−1.06) | 0.60 (0.34−1.06) | ||||
| Household income category, yen | ||||||||
| 3.7 −< 7.7 million | Reference | |||||||
| < 3.7 million | 1.26 (0.77−2.07) | 0.501 | 0.91 (0.65−1.27) | 0.032 | 1.09 (0.81−1.48) | 0.118 | 0.85 (0.65−1.12) | 0.698 |
| 7.7 −< 11.6 million | 1.19 (0.70−2.03) | 1.27 (0.87−1.87) | 1.41 (1.02−1.93) | 0.94 (0.71−1.26) | ||||
| ≥ 11.6 million | 1.81 (0.78−4.22) | 2.22 (1.18−4.19) | 0.98 (0.61−1.59) | 0.99 (0.65−1.51) | ||||
| Current hospital visit status | ||||||||
| Yes | Reference | |||||||
| None | 0.42 (0.27−0.66) | < 0.001 | 0.63 (0.45−0.89) | 0.009 | 1.82 (1.34−2.47) | < 0.001 | 0.97 (0.73−1.29) | 0.826 |
| Duration of topical corticosteroid use, years | ||||||||
| ≥ 5 | Reference | |||||||
| < 5 | 0.79 (0.51−1.20) | 0.268 | 0.76 (0.56−1.03) | 0.072 | 1.02 (0.78−1.33) | 0.879 | 1.13 (0.89−1.43) | 0.323 |
| POEM severity classification | ||||||||
| Mild | Reference | |||||||
| Moderate | 2.49 (1.59−3.90) | < 0.001 | 1.67 (1.22−2.28) | < 0.001 | 1.07 (0.81−1.43) | 0.250 | 1.36 (1.05−1.76) | 0.113 |
| Severe | 3.11 (1.41−6.88) | 1.91 (1.19−3.07) | 1.06 (0.73−1.53) | 1.32 (0.94−1.85) | ||||
| Very severe | 2.92 (0.67−12.77) | 4.04 (1.39−11.75) | 1.73 (1.01−2.95) | 1.31 (0.78−2.19) | ||||
| PGIC classification | ||||||||
| Very much improved | Reference | |||||||
| Much improved | 1.28 (0.67−2.41) | 0.782 | 1.47 (0.88−2.45) | 0.077 | 1.38 (0.67−2.82) | 0.009 | 1.08 (0.64−1.83) | 0.192 |
| Minimally improved | 1.32 (0.65−2.67) | 2.10 (1.22−3.61) | 2.30 (1.14−4.65) | 1.38 (0.82−2.35) | ||||
| No change | 0.92 (0.39−2.20) | 1.67 (0.88−3.14) | 1.96 (0.93−4.09) | 1.01 (0.57−1.79) | ||||
| Minimally, much or very much worse | 1.76 (0.21−14.91) | 1.38 (0.44−4.28) | 2.28 (0.84−6.17) | 1.04 (0.44−2.47) | ||||
| PGIT classification | ||||||||
| Extremely or very satisfied | Reference | |||||||
| Slightly satisfied | 3.68 (2.20−6.16) | < 0.001 | 2.32 (1.50−3.59) | < 0.001 | 2.50 (1.09−5.76) | < 0.001 | 1.69 (1.02−2.80) | < 0.001 |
| Neither dissatisfied nor satisfied | 8.75 (4.79−15.97) | 4.56 (2.88−7.23) | 5.14 (2.29−11.55) | 2.22 (1.34−3.65) | ||||
| Slightly dissatisfied | 25.98 (10.60−63.71) | 11.71 (6.60−20.76) | 12.04 (5.34−27.17) | 4.37 (2.62−7.27) | ||||
| Extremely or very dissatisfied | 29.28 (6.57−130.40) | 10.58 (4.77−23.50) | 14.76 (6.20−35.11) | 7.46 (4.09−13.61) | ||||
Bold indicates p-value less than 0.05 was considered statistically significant
CAM complementary and alternative medicines, OR odds ratio, PGIC Patient’s Global Impression of Change, PGIT Patient’s Global Impression of Treatment, POEM Patient Oriented Eczema Measure